Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood pressure at 12 weeks compared with placebo, according to a study presented ...

Mineralys Therapeutics (MLYS) announced detailed results from the Phase 2 Advance-HTN trial, one of two pivotal trials evaluating lorundrostat ...

What is the current share price of Mineralys Therapeutics (MLYS)? Mineralys Therapeutics's (MLYS) current share price is $14.66. This constitutes a price movement of 13.10% when compared to the share ...

The study was funded by Mineralys Therapeutics. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the ...

Shares of Mineralys Therapeutics Inc. (NASDAQ: MLYS) have surged 82% or so in the past month and were last seen trading well above the secondary offering purchase price. The stock hit a multiyear ...

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for conditions related to dysregulated aldosterone, announced it will host a conference ...

In this article, we are going to take a look at where Mineralys Therapeutics, Inc. (NASDAQ:MLYS) stands against other stocks that are receiving the most insider investment in March. “The economy ...

We recently published a list of Insiders Are Spending Big: 15 Stocks Leading in March. In this article, we are going to take a look at where Mineralys Therapeutics, Inc. (NASDAQ:MLYS) stands against ...

RADNOR, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...